Surefire Medical has announced that Gordon McLennan, Cleveland Clinic, USA, and Fred Moeslein, University of Maryland Medical Center, USA, have joined the company’s scientific advisory board.
“We are extremely fortunate to benefit from the extensive clinical expertise in interventional radiology of these doctors as we continue to develop new, first-in-class infusion systems that may enable the development of effective, minimally invasive treatments for cancer, obesity, prostate enlargement and other conditions,” said Surefire Medical president and CEO Jim Chomas.
McLennan, author of more than 34 published articles, serves as past chair of the Society of Interventional Radiology (SIR) Foundation. He is a member of the Renal Network, the Radiological Society of North America, the Society of Interventional Radiology, the Cardiovascular and Interventional Radiology Society of Europe, the American Chemical Society and the Association of University Radiologists. At the Cleveland Clinic he holds appointments in the Departments of Radiology, Biomedical Engineering and the renowned Taussig Cancer Center.
Moeslein currently serves as interim director, Division of Vascular and Interventional Radiology, at the University of Maryland School of Medicine. He is a member of the Society of Interventional Radiology, the American Medical Association, the American Academy of Sciences, the Radiological Society of North America, and the Cardiovascular and Interventional Radiological Society of Europe.
Surefire’s infusion systems are designed to precisely deliver embolic agents through a unique microcatheter with an expandable tip that collapses in forward flow and dynamically expands to the vessel wall in reverse flow in order to maximise targeted delivery, minimise reflux and reduce damage to healthy tissue.
